Even though soluble SDC-1 is already being explored as a valid biomarker in many conditions like inflammatory bowel disease [21], organ dysfunction, endothelial injury [22], and cancer [23], the association between SDC-1 and preeclampsia has not been sufficiently reviewed. As of April 2022, there is no systematic review or meta-analysis on this subject, despite the adequate number of published analytical studies. The gene discussed is SDC1; the disease is preeclampsia.